Pharmacokinetic study of lenvatinib suspension by a simple suspension method in thyroid cancer patients

Pharmacokinetic study of lenvatinib suspension by a simple suspension method in thyroid cancer patients - Pharmacokinetic study of lenvatinib suspension

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034349

Enrollment

Registered

2018-10-01

Start date

2018-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with unresectable thyroid cancers and treated with lenvatinib 2) Patients with adequate organ (liver and kidney) function for lenvatinib treatment 3) Patients aged 20 years or over 4) Patients with written informed consent Cohort: Group of patients taking lenvatinib capsules 1) Patients who can take 24 mg lenvatinib capsules Cohort: Group of patients taking lenvatinib suspension 1) Patients who can take lenvatinib suspension by the simple suspension method due to difficulty in swallowing

Exclusion criteria

Exclusion criteria: 1) Patients known to be positive for human immunodeficiency virus 2) Patients determined difficult to be included in this study based on investigator's judgement 3) Women who are pregnant,possibily pregnant, or breastfeeding 4) Patients with serious psychiatric condition

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters (AUC, Cmax, Tmax)	—

Countries

Japan

Contacts

Public ContactYoshiyuki Sano

National Cancer Center Hospital East Department of Pharmacy

yosano@east.ncc.go.jp04-7133-1111

Outcome results